NAVLIN Daily NewsCheckout Today’s News
Last week, Germany passed the GKV Stabilization Act after it cleared the Bundestag and the Bundesrat. The plan doubles drugmaker discounts to 15.5% and extends a drug price freeze until 2030. Industry has pushed back on the Act, saying it jeopardizes access to innovation and weakens Germany as a location for investment Meanwhile, a new analysis has found that Denmark's confidential pharmacy pricing pilot failed to deliver the expected results in its first year Japan's Central Social Insurance Medical Council (Chuikyo) has begun discussions on the scope and methodology of the FY2027 off-year National Health Insurance (NHI) drug price revision
Ireland's National Center for Pharmacoeconomics (NCPE) became the first HTA agency to complete a national assessment for Novartis' Itvisma, undergoing an EU Joint Clinical Assessment (JCA), using the JCA report to inform its rapid review before the report's public releaseThe NCPE issued an unfavorable reimbursement recommendation, advising that Itvisma not be considered for reimbursement at the submitted price and did not recommend a full HTAIreland issued its national reimbursement recommendation only 16 days after EU marketing authorization and before the European Commission is expected to publish the JCA report in early August 2026
Novo Nordisk will launch Extensior, a lower-cost authorized copy of its diabetes medicine Ozempic (semaglutide), in South Africa on July 27 It will be launched through a partnership with healthcare company Acino in the same 0.25 mg, 0.5 mg, and 1 mg doses as Ozempic and will be priced below the branded product"Prices around this will be confirmed to the market next week. I can confirm that Extensior will be cheaper than (branded) semaglutide for use in type 2 diabetes," Sara Norcross, General Manager of Novo Nordisk South Africa, told Reuters
According to a report by Kun.uz, Uzbekistan lowered the reference price ceilings for 2,500 prescription medicines sold in pharmacies effective July 1, 2026, with price reductions of up to 50.1% across several major therapeutic categories under its state-regulated reference pricing systemThe Agency for the Development of the Pharmaceutical Industry spokesperson, Anvar Akabirov, said prices for antibiotics and antimicrobial medicines were reduced by up to 50.1%, cardiovascular diseases saw price cuts of up to 37%, while drugs affecting the nervous system became up to 40% cheaper. Prices for anti-inflammatory medicines and painkillers were reduced by as much as 42%Akabirov said pharmacies can no longer sell medicines covered by the revised reference prices under the previous price ceilings
The National Institute for Health and Care Excellence (NICE) has published its 2025–2026 Annual Report and Accounts, highlighting key achievements, operational improvements, and strategic priorities over the period from April 2025 to March 2026During the reporting period, NICE completed 98 medicine evaluations, recommending 66 medicines, terminating 25 appraisals, and issuing seven negative recommendationsThe report highlights faster guidance development, with medicines appraisals completed 30% faster and health technology guidance 9% faster since April 2024
Sun Pharma to launch its generic semaglutide injection in South Africa in the coming days for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise The launch follows approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market the product in the country"South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets," said Aalok Shanghvi, Chief Operating Officer, Sun Pharma
Germany’s Bundestag has passed the proposed Statutory Health Insurance Contribution Rate Stabilization Act (GKV-BStabG), with 318 votes in favor, 284 against, and four abstentionsFederal Health Minister Nina Warken underscored, "We have found a solution for the pharmaceutical industry that gives companies greater planning certainty." However, Warken stressed that pharma companies will still have to make an "appropriate contribution" to the financial consolidation of the GKV. The dynamic manufacturer discount originally envisaged will be replaced by a statutory increase in the static manufacturer discount to 15.5%. Meanwhile, the additional discount for patented vaccines will be increased to 9%. In addition, a price moratorium will be established for these vaccines used in preventive immunizations from January 1, 2027, through December 31, 2030The bill now heads to the Bundesrat, the upper house of parliament representing Germany’s 16 federal states, where the vote has already been postponed until the end of the 1067th plenary session . Some regional leaders have already stated they will not support a fast-track procedure. If the bill fails to secure a majority in the Bundesrat, it will be sent to a political Mediation Committee to negotiate a compromise
Last week, NAVLIN Daily brought you key market access developments from across the globeIn Europe, Germany's governing coalition agreed to abandon plans for an annually recalculated manufacturer discount in favor of a higher fixed rebate, while the EC published the second and third JCA reports under the EU HTA Regulation. Elsewhere, Denmark officially launched its MFN task forceIn the U.S., CMS proposed reforms to the 340B Drug Pricing Program, while the administration's Unified Agenda outlined HHS regulatory priorities that could impact the pharmaceutical industry
Germany’s Federal Constitutional Court has rejected urgent applications by two opposition MPs against the legislative process on the Statutory Health Insurance Contribution Rate Stabilization Act (GKV-BStabG)According to the German Press Agency (dpa), two members of the Bundestag from the Greens and the Left Party had each turned to the highest German Court with urgent applications because they considered the urgent legislative procedure to be inadmissible. The governing coalition had presented 278 pages of amendments just a few days before the planned voteHowever, as the Court rejected the applications, the Bundestag will be cleared to vote on the legislation as planned for July 10
Novo Nordisk has launched Awiqli (insulin icodec), its once-weekly basal insulin, in India, expanding treatment options for adults with diabetes by reducing the number of insulin injections from 365 to 52 annuallyThe product will be rolled out in the Indian market next weekA once-weekly dose of 70 insulin units of Awiqli costs 261 Indian rupees (about $3.07), Novo Nordisk India Managing Director Vikrant Shrotriya told reporters at the launch in New Delhi
650+
+99%
<24
4,000+
24x7
99.5%
